| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 61.23 | 9.0% |
| Total Income | 62.92 | 8.7% |
| Expenditure | 49.08 | 1.1% |
| PBT | 13.84 | 67.8% |
| Net Profit | 10.22 | 82.0% |
| OPM | 23.84% | 16.16pp |
| NPM | 16.24% | 6.54pp |
| EPS | 6.47 | 74.4% |
Kilitch Drugs Q4FY25 PAT Surges 212% YoY, Revenue Rises 44% on Standalone Basis
22 May 2025 · 22 May 2025, 05:22 pm
Summary
Kilitch Drugs Limited, a leading pharmaceutical company, announced its unaudited financial results for the quarter ended on 31 March 2025. The company reported a 178% YoY rise in consolidated profit after tax (PAT) to Rs. 1,021.86 lakh and a 37% YoY growth in consolidated revenue from operations to Rs. 6,122.58 lakh. Standalone PAT rose by 212% and revenue grew by 44% to Rs. 1,137.41 lakh and Rs. 18,158.73 lakh, respectively. The company's standalone net profit for FY25 increased by 77% to Rs. 3,115.69 lakh.
Key Highlights
- 1
Q4FY25 consolidated PAT up by 178% YoY
- 2
Q4FY25 consolidated revenue from operations up by 37% YoY
- 3
Standalone PAT up by 212% in Q4FY25
- 4
Standalone revenue up by 44% in Q4FY25
- 5
FY25 standalone net profit up by 77%
Management Comments
Mr. Mukund Mehta
We witnessed significant growth in our performance for this year; revenue from operations grew by 44% and PAT increased by 212% on standalone basis as compared to Q4FY2024. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders.
Informational and educational content only. Not investment advice.